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The loss of transglutaminase 1 enzyme (TGase 1) ac-
tivity causes lamellar ichthyosis. Recessive X-linked ich-
thyosis (XI) results from accumulation of excess choles-
terol 3-sulfate (CSO4) in the epidermis but the
pathomechanism how elevated epidermal CSO4 causes
ichthyosis is largely unknown. Here we provide evi-
dence that XI is also a consequence of TGase 1 dysfunc-
tion. TGase 1 is a key component of barrier formation in
keratinocytes: it participates in the cross-linking of cell
envelope (CE) structural proteins, and also forms the
lipid bound envelope by esterification of long chain
v-hydroxyceramides onto CE proteins. Using involucrin
and an epidermal v-hydroxyceramide analog as sub-
strates, kinetic analyses revealed that at membrane con-
centrations above 4 mol %, CSO4 caused a marked and
dose-dependent inhibitory effect on isopeptide and es-
ter bond formation. Sequencing of tryptic peptides from
TGase 1-reacted involucrin showed a large increase in
deamidation of substrate glutamines. We hypothesize
that supraphysiological levels of CSO4 in keratinocyte
membranes distort the structure of TGase 1 and facili-
tate the access of water into its active site causing hy-
drolysis of substrate glutamine residues. Our findings
provide further evidence for the pivotal role of the
TGase 1 enzyme in CE formation.
Assembly of an effective epidermal barrier structure is an
essential adaptation to terrestrial life. In mammals the outer-
most bulwark of this barrier is the cornified layer of the epi-
dermis, composed of flattened corneocytes mortared together
by orderly lipid laminae. During terminal differentiation, indi-
vidual corneocytes acquire a specialized cell peripheral struc-
ture termed the cornified cell envelope (CE),1 which is respon-
sible for maintenance of mechanical and chemical protection
and indirectly contributes to water permeability barrier (see
Refs. 1 and 2, for reviews). The CE is composed of two parts.
The ;10 nm thick protein envelope is formed by covalent
cross-linking of several structural proteins by sulfhydryl oxi-
dases and transglutaminases (TGases). This highly insoluble
protein meshwork is coated by the lipid envelope, a ;5 nm
thick layer of v-hydroxyceramides with uniquely long (C28-C36)
fatty acyl moieties (3). These are covalently attached by ester
bonds through their v-hydroxyl group to selected glutamines to
envoplakin, periplakin, and involucrin components of the pro-
tein envelope (4).
Terminal differentiation of keratinocytes is accompanied by
vigorous lipid metabolism and synthesis of keratinization-spe-
cific lipids in the granular layer. Newly synthesized lipids are
temporarily stored in cytoplasmic lamellar bodies, in which
they are arranged as stacks of tetralaminar sheets. The lamel-
lar body lipids consist largely of free fatty acids, (glucosyl)cer-
amides, cholesterol, and its acyl or sulfate esters (3). In the
uppermost granular layer the lamellar bodies fuse with the cell
membrane, and release their contents which assume broad,
multilamellar lipid sheets between corneocytes. This process
approximately coincides with the initiation of assembly of both
the protein envelope and lipid envelope of the CE (5). It is
thought that the ester-linked long chain v-hydroxyceramides
comprising the lipid bound envelope interdigitate with the
interstitial lipid layers and might function in a Velcro-like
fashion by fixing the protein envelope to surrounding lipid
structures, and vice versa. In this way, the lipid bound enve-
lope contributes to the maintenance of an orderly array of lipid
layers during normal wear and tear and mechanical stress of
the epidermis.
Genetic errors of CE and skin barrier formation can manifest
as ichthyosiform symptoms. Some of these diseases have been
distinguished on the basis of abnormal metabolism of stratum
corneum lipids (6, 7). Some congenital ichthyoses reveal abnor-
mal deposition of apolar or polar lipids or cholesterol in the
intercorneocyte lipid layers, and thereby appear to disrupt the
normal lipid layerings and composition required for effective
epidermal barrier function (8). These include recessive
X-linked ichthyosis (XI) which is caused by an accumulation of
excess cholesterol 3-sulfate (CSO4) owing to arylsulfatase
C/cholesterol sulfatase enzyme defects (9).
CSO4 is a ubiquitous cholesterol metabolite, the amount of
which is determined by the relative activity of cholesterol sul-
fotransferase and cholesterol sulfatase enzymes (10). CSO4
gradually accumulates during epidermal keratinocyte differen-
tiation, peaking normally at levels of 4–5% of total lipids in the
upper stratum granulosum and it is hydrolyzed in the cornified
layer, so that normal corneocyte scales contain less than 1%
CSO4 of total lipids (11, 12). In XI the lack of its breakdown
results in an elevated CSO4 content in the basal and spinous
layers, peaking at .10% (by weight) of total lipids in the
stratum corneum (13).
However, it is not yet clear how excessive epidermal CSO4
diminishes barrier function in the epidermis, and whether the
mild increase of epidermal (water) permeability alone is suffi-
cient to account for the severe symptoms of the disease. Several
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published reports have addressed the alterations of physical
properties of corneocyte lipids from excess CSO4 (14–16). It has
been shown that CSO4 can cause phase separation of choles-
terol-fatty acid layers (14) and that the XI phenotype can be
ameliorated by topical cholesterol treatment (17). Thus it was
suggested that XI arises due to a defect of intercorneocyte lipid
layer formation. In a conceptually related argument, CSO4 was
shown to interfere with spontaneous sheet formation of epider-
mal lipids in vivo, perhaps due to the strong charge of its
sulfate moiety conferring detergent properties to CSO4. Thus it
was theorized that CSO4 affects epidermal barrier function
both by deranging skin lipid layers and by replacing cholesterol
in the lipid sheets (16). In another study, it was proposed that
since CSO4 has trypsin and chymotrypsin inhibitory properties
in vitro, it might thereby affect breakdown of desmosomes, thus
causing retention hyperkeratosis and abnormal scaling (18).
Finally, more recently, it was demonstrated that CSO4 can
induce TGase 1 expression in cultured keratinocytes (19), but
the connection between excess TGase expression and disease
etiology remains unclear. CSO4 in keratinocyte membranes
was shown to activate the protein kinase C isoforms e, z, and h,
presumably by direct allosteric effects on their tertiary struc-
tures. As these membrane-bound enzymes are involved in the
signaling pathways of keratinocyte differentiation (20, 21),
CSO4 could induce TGase 1 expression in this way (19).
Mammalian TGases (glutamyl-amine aminotransferases,
EC 2.3.2.13) constitute an evolutionarily related family of Ca21-
dependent enzymes (22). The catalytic mechanism of TGases
involves the release of ammonia from the reactive glutamine
residues, and the residual glutamyl moieties form an acyl-
enzyme thioester, a labile intermediate susceptible to nucleo-
philic attack by primary amines, notably e-amino groups from
protein bound lysines (forming Ne-(g-glutamyl)lysine isopep-
tide cross-links), or polyamines (resulting in N,N9-bis(g-glu-
tamyl)polyamine cross-links (23, 24). However, the thioester
intermediate can also be transferred to primary alcohols (25,
26). We have shown that in the epidermis, the terminal (v)
hydroxyl group of v-hydroxyceramides is an effective substrate
for membrane-bound TGase 1, and this route links these lipids
to protein-bound glutamines by an ester bond (27). Lastly,
water can also enter the active site of TGases to attack the
acyl-enzyme intermediate, which leads to a net deamidation of
a reactive glutamine to a glutamic acid residue (28, 29).
Seven members of the TGase family have been identified in
the human genome so far, of which four (TGases 1, 2, 3, and X)
are expressed in the epidermis (30, 31), although to date only
TGases 1 and 3 have verified roles in CE assembly (32, 33).
TGase 1 is expressed as a 106-kDa monomeric protein, which is
constitutively N-myristoylated and S-palmitoylated on its ami-
no-terminal 10-kDa domain, thereby directing the enzyme to
plasma membranes (34–36). Membrane-bound TGase 1 en-
zyme is essential for both the assembly of the protein envelope
by cross-linking CE structural proteins located in the intimate
vicinity of the cellular membrane, and the esterification of the
v-hydroxyceramides to proteins, primarily involucrin (27). Ge-
netic defects of TGase 1 cause the often devastating disease
lamellar ichthyosis (37, 38). The homozygous TGase 1 knock-
out mice show defective CE assembly and die from dehydration
a few hours after birth (39).
Involucrin is ubiquitously expressed in stratified squamous
epithelia, suggesting it is commonly involved in CE formation
(40, 41). Mammalian involucrins evolved by tandem duplica-
tions of glutamine and glutamic acid-rich sequences spanning
between the evolutionary relatively conserved amino-terminal
(“head”) and carboxyl-terminal (“tail”) domains (42). Recent in
vivo observations indicate that the CE formation may be initi-
FIG. 1. Cross-linking of involucrin by TGase 1 on SLV. Recom-
binant human 35S-involucrin was incubated with TGase 1 attached to
SLV containing 15% phosphatidylserine (and no CSO4) in the presence
of Ca21 for 60 min. 20-mg aliquots of involucrin products were separated
by SDS-PAGE, transferred onto membranes, and detected by autora-
diography. A, involucrin formed intrachain cross-links (I), dimers (D),
trimers (T), and unresolved higher oligomers (O). B, cross-linking of
involucrin was not impeded by the inclusion of 1 mol % lipid Z ceramide
substrate; C, oligomerization was inhibited by 20 mM putrescine. D, in
the case of the K62N mutant form of involucrin, no cross-linking
occurred.
FIG. 2. Identification of cross-linking sites in involucrin. C18
HPLC profiles of tryptic involucrin peptides were compared before (A)
and after (B) reaction with TGase 1 bound to SLV containing no CSO4.
Peaks harboring the 5 Gln residues reactive with SLV-bound TGase 1
are indicated with arrows on panel A. For clarity, the same peak
numbering system was retained as before (44). TGase 1-dependent
appearance of the novel peaks P1 and P2 is noted. The sequences of
these peaks are shown in Table I.


















ated by the deposition of a monomolecular layer of involucrin
on the inner keratinocyte membrane (41, 43). In a previous
paper (44) we described an in vitro model system for charac-
terizing the function of TGase 1 on the surface of synthetic lipid
vesicles (SLV) of composition similar to eukaryote plasma
membranes. Using this model system we have demonstrated
that involucrin is absorbed to membranes containing physio-
logical levels of phosphatidylserine at Ca21 concentrations in
the range typically seen in keratinocytes.
Applying our SLV experimental system for modeling the
earliest stages of CE assembly, we demonstrate here that su-
praphysiological levels of CSO4 severely interfere with involu-
crin cross-linking and v-hydroxyceramide esterification by
TGase 1. Our data reveal new insights into the pathophysiol-
ogy of XI disease.
MATERIALS AND METHODS
Production of Recombinant TGase 1 and Human Involucrins—Full-
length human TGase 1 and involucrin proteins were expressed and
purified exactly as described (44). A K62N mutant form of human
involucrin was made from the pET11a expression plasmid by use of the
GCACATGACTGCTGTAACGGGACTGCCTGAGCAAGAATG primer
and its reverse strand using the QuickChange (Stratagene) kit, and
further processed identically to the wild type. Occasionally, involucrin
expression was induced in a LB broth containing 100 nmol (0.5 mCi/
liter) of L-[35S]cysteine and 100 nmol (0.5 mCi/liter) of L-[35S]methionine
(both from Amersham Pharmacia Biotech).
Preparation of SLV—The following mixtures were made in chloro-
form/methanol (2:1): 55 mol % dimyristoyl phosphatidylcholine, 15 mol
% dipalmitoyl phosphatidylserine, 0–10 mol % CSO4, cholesterol up to
99 mol % (all from Sigma), and 1 mol % of the synthetic ceramide analog
N-[16-(16-hydroxyhexadecyl)oxypalmitoyl]sphingosine (lipid Z) (27).
The solvent was evacuated, and the lipids were taken up in aqueous
buffer and dispersed by sonication as before (44). The prepared SLV
suspension was equipped with 0.94 pmol (0.1 mg) of TGase 1 and its
membrane binding was facilitated by incubating at 37 °C for 15 min
prior to adding substrates.
Cross-linking of Involucrin by TGase 1—SLV (200 ml, 2 mmol of lipid)
formulated with 0–10 mol % CSO4 were loaded with TGase 1 as above
and 600 pmol (40 mg) of involucrin in the presence of 1 mM CaCl2. They
were immediately incubated for 2 h in either the absence or presence of
20 mM putrescine with 100 nCi of [14C]putrescine (NEN Life Science
Products Inc., Boston, MA, 110 Ci/mmol). The reactions were stopped by
the addition of EDTA to 10 mM. In control experiments we assessed
whether the applied concentrations of CSO4 disrupted or aggregated
the SLV. SLV confectioned with 0–15 mol % CSO4 and the above
ingredients in various combinations were diluted 10-fold in reaction
buffer (without isotope) and examined by light scattering at 310 nm. As
we found no changes in light scattering for CSO4 concentrations below
12 mol %, we routinely used SLV containing #10 mol % CSO4.
Analysis of Cross-linking of Involucrin by TGase 1—The above reac-
tion mixtures were diluted with SDS-PAGE sample buffer (45), boiled,
and analyzed by autoradiography after transfer onto polyvinylidene
difluoride membranes following SDS-PAGE on 4–20% gradient gels
(Novex). In some experiments, 0.1 ml of 20% SDS was added to the
samples and the mixture was vortexed. This mixture was precipitated
and washed three times with acetone/triethylamine/acetic acid (90:5:5)
(46) to remove the SDS and noncovalently bound lipids. After further
washing with acetone, the pellet was dried under vacuum and redis-
solved in 50 mM Tris-HCl (pH 7.5). Quantitation of the Ne-(g-glutamyl)
lysine isopeptide cross-link was done by amino acid analysis following
exhaustive proteolytic fragmentation of the products by the nonspecific
protease Pronase and a mixture of carboxypeptidases (47).
Determination of Kinetic Parameters of 14C-Putrescine Incorporation
by TGase 1—Vmax, Km, and kcat values were determined exactly as
described (44).
Isolation and Quantitation of Lipid Z Esterification of Involucrin
Reactive Glutamines by TGase 1—The tryptic peptides of involucrin
reacted with TGase 1 on SLV formulated with 1% lipid Z for 2 h were
recovered and quantitated exactly as described (27).
Analysis of Cross-linking and Deamidation of TGase 1 Reactive Glu-
tamine Residues in Involucrin—There are four different outcomes of
TGase catalysis of reactive Gln residues in the present experimental
system, and are as follows: deamidated (that is, a Glu residue is
formed); ester-linked to the synthetic ceramide analog lipid Z; and
isopeptide cross-linked, either to the Ne-amino group of an involucrin
Lys residue or, where added, to the diamine substrate putrescine form-
ing g-glutamylputrescine (EP). Finally some substrate glutamine resi-
dues are recovered in unmodified form. The following procedures were
designed to separately identify and quantitate each of these five end
products. Samples of TGase 1-reacted involucrin were freed from SLV
lipids as above. The protein was then digested with 2% (by weight)
modified trypsin (Roche Molecular Biochemicals). The grossly different
chromatographic properties of Ne-Lys62 cross-linked and lipid Z-linked
tryptic involucrin peptides allowed their separation and quantitation by
amino acid analysis following acid hydrolysis. In the samples reacted
with lipid Z, first the digest was passed through a C4 HPLC column
under strongly desorbing solvent conditions as described (27), where
only the lipopeptides are retarded and all other non-lipid-containing
peptides are recovered in the column flow-through (4). The amount of
FIG. 3. Increasing amounts of CSO4 inhibits of involucrin
cross-linking. Formation of cross-linked oligomers from involucrin
was analyzed at different SLV membrane CSO4 concentrations as in
Fig. 1. Reduction of cross-linked products is apparent above 6 mol %
CSO4.
TABLE I
Amino acid sequences of peptide peaks from HPLC separation of
tryptic involucrin peptides (Fig. 2B) affected by cross-linking by TGase
1 on SLV








P1 QEEK62 HMTAVK 59–63
:
LLDQQ133LDQELVK 129–140
P2 QEEK62 HMTAVK 59–63
:
QEAQLELPEQQ496VGQPK 486–501


















the five lipid Z-ester linked peptides (see Fig. 5A) was determined by
amino acid analysis. The peptide pool recovered from the C4 column
flow-through was further separated by C18 HPLC chromatography as
described (44). Here peptides involved in cross-link formation were
recovered as distinct peaks (P1 and P2 of Fig. 2B) when cross-linked to
another involucrin peptide. Sequences and cross-linking sites of these
peptides were determined by peptide sequencing as before (48). To
eliminate interference of overlapping (non-cross-linked) tryptic pep-
tides of involucrin, the absolute molar amount of cross-linked residues
was calculated from the Thr content, since Thr was absent from neigh-
boring contaminating peptide peaks and was equimolar with the N-e(g-
glutamyl)lysine isopeptide present in the cross-linked peptide (Table I).
However, the peptides harboring unmodified, deamidated or pu-
trescine-linked glutamine residues were not resolvable by HPLC but
instead were analyzed by peptide sequencing. After Edman degrada-
tion, the phenylthiohydantoin-derivatized residues each appeared as a
distinct peak in the sequencer’s HPLC profile (see Fig. 6). The ratio of
deamidation and putrescine cross-linking was determined from the
relative intensity of PITC/phenylthiohydantoin-derivatized Gln, Glu,
and EP peaks from the sequencing cycles corresponding to each ex-
pected Gln residue as four of the reactive Gln residues were preceded by
an unreactive Gln, the ratio of the unmodified and deamidated Gln/Glu
residues was corrected for carryover from the previous sequencing cycle
of Gln, using the formula,
Q/E 5
@Qn 2 Qn21 z ~1 2 Qn11/Qn!#@1 1 En21 1 En21!]
@En 2 En21 z ~1 2 En11/En!#@1 2 En21/~Qn21 1 En21!#
(Eq. 1)
where Xn denotes the amount of the amino acid released from the
sequencing cycle corresponding to the reactive residue position, and
Xn21, or Xn11 denote the yield of the same amino acid in the previous or
consecutive sequencing cycle. Similarly, the amount of EP was cor-
rected for incomplete cleavage and carryover by the formula,
EP 2 (EPn)2 z ~EPn/~EPn 2 EPn11! (Eq. 2)
Where EPn denotes the amount of g-glutamylputrescine in the first
cycle of its appearance and EPn11 is that from the next cycle. Molar
absorption of EP was taken equal to that of Lys at the detection
wavelength of the Porton 3000 sequencer (268 nm). Thus based on the
directly measured absolute amounts of Gln residues occupied by the
Ne-(g-glutamyl)lysine cross-link and the lipid Z ester, we could calculate
from the sequencing chromatograms the fate of the remainder of the
600 pmol of the Gln residues of involucrin that was unreacted, deami-
dated, and in control experiments, putrescine-linked. The data repre-
sent the means of three or more independent measurements.
RESULTS AND DISCUSSION
Involucrin is Cross-linked to Itself by TGase 1 on SLV—Wild
type 35S-involucrin was reacted with TGase 1 on the surface of
SLV for 2 h in the absence of exogenous glutamyl acceptor
substrates. The protein was cross-linked into dimers, trimers,
tetramers, and higher oligomers, as evidenced by autoradiog-
raphy of protein blots after separation by SDS-PAGE (Fig. 1A).
Some of the protein showed faster electrophoretic mobility than
the monomer, indicative of intramolecular cross-link formation
(49). Oligomers larger than tetramers were not separated by
the gels used, but remained at the interface of the separation
gel. Inclusion of 1 mol % lipid Z into the SLV membranes did
not eliminate involucrin cross-linking by TGase 1 (Fig. 1B), but
the addition of 20 mM putrescine as a competitive inhibitor of
protein bound lysine e-amino groups (Fig. 1C) or omission of
Ca21 (not shown) caused a virtually complete inhibition of
oligomer formation. These data indicate that involucrin is a
complete substrate for the TGase 1 enzyme bound to SLV, in
that it provides both donor Gln and acceptor Lys residues, and
confirm a similar conclusion for the reaction of crude TGase 1
with involucrin in solution assays (49).
TGase 1 Forms Intermolecular Cross-links between Lys62 and
Gln496 or Gln133 Residues of Involucrin—In order to identify
the residues involved in the oligomerization by cross-linking of
involucrin, following TGase 1 reaction on SLV and fragmenta-
tion by trypsin, peptides were separated by C18 reverse-phase
HPLC, and the elution profile of obtained peptide peaks was
compared with that of the uncross-linked protein (44) (Fig. 2, A
and B). The cross-linking by TGase 1 caused the appearance of
two novel peaks (P1 and P2 on Fig. 2B), and concomitant
reduction of the relative intensity of three peaks compared with
the initial profile. Protein sequencing revealed that the novel
peaks resulted from cross-link formation of two Gln donor
peptides with a single Lys (Table I) and that the residues
involved in Ne-(g-glutamyl)lysine cross-linking were Gln496 or
Gln133 with Lys62, respectively. No other novel potentially
cross-linked peaks with yields .0.005 mol/mol of involucrin
were found. Given the large numbers of Gln and Lys residues
in involucrin (50), this remarkable degree of specificity leading
to both head-to-tail and head-to-head oligomerization provides
further evidence for the importance of the membrane surface in
directing TGase 1 specificity. Identical results were obtained if
1 mol % lipid Z incorporated into SLV was offered as an alter-
native glutaminyl acceptor substrate (data not shown), in
agreement with previous findings that isopeptide bonds formed
by amine substrates are energetically more favored products of
TGase catalysis that ester bonds (27).
Interestingly, Lys62 has been precisely conserved in all mam-
malian involucrins (42), inferring that oligomerization through
this residue is an ancient aspect of CE formation. However,
cross-links involving Lys62 were not found in CEs recovered
from mature foreskin epidermal stratum corneum tissue (41),
FIG. 4. Activity of membrane-bound TGase 1 at different SLV
CSO4 concentrations measured by [
14C]putrescine incorpora-
tion. A, radioactive putrescine incorporation into involucrin (circles)
and succinylated casein (triangles) substrates showed no significant
(p , 0.05) dependence from membrane CSO4 levels under standard
assay conditions, when [14C]putrescine was given at 20 mM concentra-
tion. However, if 1 mM putrescine was used instead (B), the inhibition
of activity was apparent at 5 or higher mol % membrane CSO4. The
phenomenon is indicative of competitive inhibition.


















but cross-links between Lys62 and Gln496 or Gln133 were com-
monly observed in CEs formed in cultured keratinocytes (51).
Likewise, although Gln133 is not conserved in prosimians (42),
cross-linked peptides involving it were found in cultured kera-
tinocyte CEs. As these keratinocytes undergo only a limited
degree of barrier formation, we can conclude that cross-linking
though Lys62 or Gln133 should represent early stages of CE
assembly, and that the numerous other Lys and Gln residues
identified in our in vivo studies must be utilized in later stages
(51).
K62N Mutant Involucrin Is Not Oligomerized by SLV-Bound
TGase 1—As a control for the cross-linking through the sole
Lys62 residue, we made a K62N mutant form of involucrin. This
completely eliminated the ability of involucrin to serve as com-
plete substrate for TGase 1 on SLV, as autoradiography after
SDS-PAGE showed no detectable inter- or intrachain cross-
linked involucrin products (Fig. 1D). Likewise, the HPLC pro-
file of tryptic peptides of the involucrin mutant showed no sign
of the TGase 1-mediated changes which were observed with the
wild type protein (although as expected, peak 9 disappeared
since a trypsin cleavage site was lost as a consequence of the
mutation, and another new peak appeared (data not shown)).
Effect of CSO4 Content in SLV on Involucrin Cross-linking by
TGase 1—The effect of CSO4 on the membrane-dependent
cross-linking of involucrin was examined by formulating the
carrier SLV with 0–10 mol % CSO4 in 2% increments. CSO4
concentrations above 12% began to destabilize SLV assembly
and therefore were not used. Analysis of the electrophoretic
mobility of TGase 1-treated 35S-involucrin revealed a CSO4
concentration-dependent inhibition of cross-linking, which was
apparent at 6 mol % and almost completely eliminated the
bands of inter- or intramolecularly cross-linked involucrin at
10% (Fig. 3A). Assaying the amounts of Ne-(g-glutamyl)lysine
isopeptide cross-link showed a significant decline of cross-link
amount at 6 mol % CSO4 (p , 0.001) and which was reduced to
,10% at 10 mol % CSO4 (Fig. 3B).
TGase 1 activity was assayed by using a large excess of
[14C]putrescine as the amine substrate with both involucrin
and the standard TGase assay substrate succinylated casein.
Incorporation of the labeled amine was not significantly af-
fected at any concentration below 8 mol % CSO4 and only a
slight decrease (p , 0.1) of activity was noted at 10 mol % (Fig.
4A). Kinetic parameters of [14C]putrescine incorporation into
involucrin and the standard substrate succinylated casein,
which does not adsorb to SLV under these conditions (44) were
measured (Table II), and indicated that up to 10 mol % CSO4
there was no statistically significant (p , 0.1) change in the
apparent Vmax of TGase 1. However, when 1 mM putrescine was
used, SLV CSO4 content caused a dose-dependent decrease of
the reaction rate. The assay of kinetic parameters revealed
only an insignificant effect of CSO4 on Vmax with both protein
substrates. However, for the substrate putrescine, membrane
CSO4 caused a dose-dependent increase of Km(app) and thus
reduced the catalytic efficiency (Kcat/KM) values, a phenomenon
characteristic of competitive inhibition.
Effect of SLV Content of CSO4 on v-Hydroxyceramide Ester-
ification by TGase 1—In addition, we explored the effects of
CSO4 on TGase 1-mediated v-hydroxyceramide attachment to
involucrin by esterification. One mol % of the artificial v-hy-
droxyceramide analog lipid Z was incorporated into the SLV
and reacted with involucrin by TGase 1 as before (27). Isolation
of peptide-linked ceramides was done by C4 HPLC separation
of tryptic peptides of involucrin under strongly desorbing sol-
vent conditions, where only the lipopeptide adducts are re-
tarded and free peptides elute with the column flow-through
(4). Amounts of recovered peptide-lipid Z adducts showed a
visible decline of peak areas in SLV containing $4 mol % CSO4
content (Fig. 5A). Quantitative analysis of these peaks by
amino acid analysis after acid hydrolysis indicated a significant
decrease of summed lipopeptide formation at 4 mol % (p ,
0.001) SLV CSO4 content, a 10-fold reduction at 8 mol %, and
.30-fold less with 10 mol % CSO4 (Fig. 5B).
Taken together, the inhibition of isopeptide cross-linking and
ester formation imply that CSO4 serves as a competitive inhib-
itor of TGase 1 reactions. However, since CSO4 is clearly not a
substrate for TGases, it is possible that instead it interferes
with the reaction by limiting access to the active site for sub-
strates or by conformational alteration of the enzyme. In order
TABLE II
Apparent kinetic parameters for putrescine incorporation into involucrin and succinylated casein by 0.94 pmol membrane bound TGase 1 at
different membrane CSO4 concentrations
All SLV were formulated with 55% phosphatidylcholine and 15% phosphatidylserine. KM(app) values pertain to the protein, unless otherwise
stated. Vmax and Kcat data are that of putrescine incorporation. Values with 0% CSO4 are the same as published before (30).
Vmax Kcat(putrescine) KM(app) Kcat/KM
pmol min21 min21 mM min21 nM
0% CSO4
Putrescine 400 6 50
Succinylated
casein
3.2 6 0.2 3.4 145 6 18 23 6 5
Involucrin 2.4 6 0.4 2.55 2.9 6 0.4 880 6 90
4% CSO4
Putrescine 530 6 65
Succinylated
casein
3.4 6 0.3 3.6 125 6 16 28 6 4
Involucrin 2.7 6 0.3 2.9 2.8 6 0.3 1030 6 120
6% CSO4
Putrescine 715 6 95
Succinylated
casein
1.6 6 0.2 1.7 161 6 21 10 6 3
Involucrin 1.9 6 0.3 2.0 3.9 6 0.5 520 6 105
8% CSO4
Putrescine 920 6 130
Succinylated
casein
0.6 6 0.2 0.64 193 6 18 4 6 1.3
Involucrin 0.35 6 0.1 0.37 5.2 6 0.6 70 6 25


















to resolve these issues in detail, we analyzed the fate(s) of each
reactive Gln residue using different substrate conditions.
Analysis of TGase 1-mediated Modifications of Reactive Gln
Residues in Involucrin with Increasing SLV CSO4 Content—
Five Gln residues (Gln107, Gln118, Gln122, Gln133, and Gln496) of
involucrin serve as substrates for membrane-bound TGase 1
(27, 44). Each of these Gln residues can undergo either hydrol-
ysis or ester bond formation or transglutamination as one of
four fates of each reactive Gln residue, we formulated SLV with
different membrane CSO4 contents, and used the following
different substrate conditions: wild type involucrin or its K62N
mutant were reacted either with only itself, or with 1 mol %
lipid Z in SLV. As controls, we also used 20 mM putrescine as a
competitive inhibitor, in which case the EP derivative is
formed.
Following reaction, involucrin was fragmented with trypsin,
and where applicable, lipid Z-attached peptides were extracted
from the peptide pool by selective retardation on the C4 HPLC
column (Fig. 5A). Lipopeptides were quantified by amino acid
analysis following acid hydrolysis. The remainder of the pep-
tides was lyophilized and separated by C18 HPLC. Peaks har-
boring reactive Gln residues were collected based on their
known chromatographic elution properties (44). Peaks of cross-
linked peptides (Fig. 2B) were also collected and quantified.
The peaks harboring TGase 1-reactive glutamines embraced a
mixture of glutamine-derived moieties, that were either un-
modified, deamidated to glutamic acid, or eventually modified
to EP. These products were collected in the same fraction, and
sequenced as a mixture. The phenylthiohydantoin-derivatives
of Gln, Glu, and EP from TGase 1 substrate residues Gln107,
Gln118, Gln122, Gln133, and Gln496 were measured in the appro-
priate sequencing cycles (Fig. 6) and peak area derived abso-
lute molar amount values were corrected for carryover from
previous cycles, spontaneous deamidation, and coupling yield
by pristine algebra. Data for all five glutamines are summa-
rized in Table III.
When wild type involucrin was reacted with TGase 1 on SLV
formulated without CSO4 in the absence of any other glutamyl-
acceptor substrate, 51% of the Gln496 residue was modified, of
which most was engaged in cross-link formation with Lys62
(Fig. 7A). Inclusion of increasing amounts of CSO4 into SLV
greatly decreased the percentage utilization of the Gln496 for
cross-link formation, but steadily increased the amount of de-
amidation, so that in SLV with 10% CSO4, 53% was deami-
dated and only 8% was used for cross-link formation. Similar
deamidation rates were seen for the Gln133 residue which also
participated in cross-link formation. For Gln107, Gln118, and
Gln122 which did not engage in Ne-(g-glutamyl)lysine cross-link
formation with Lys62, most was likewise deamidated (Fig. 7G,
other data not shown). Next, we used SLV containing 1 mol %
of the synthetic v-hydroxyceramide substrate lipid Z. In the
case of Gln496, 1 mol % lipid Z could not effectively compete out
the isopeptide cross-link formation, but about 5% was used for
ester formation in the absence of CSO4 (27) (Fig. 7B). However,
all was lost to deamidation by 6% membrane CSO4. For Gln
107,
Gln118, Gln122, and Gln133, 20–30% was used for ester forma-
tion in the absence of CSO4, and again, an increasing percent-
age of deamidation eradicated this reaction product by 8–10
mol % CSO4 (Fig. 7H for Gln
122, other data not shown). Finally,
addition of 20 mM putrescine to the above system led to near
complete modification of Gln496 to EP and efficiently sup-
pressed the cross-linking and deamidation by TGase 1 as ex-
pected (44). Even so, there was a small but significant increase
in deamidation rate at the highest levels of CSO4 tested (Fig.
7C). Essentially identical results were seen with the other four
FIG. 5. Increasing amounts of CSO4 inhibits of involucrin es-
terification. Involucrin was reacted with TGase 1 on SLV confectioned
with 1 mol % of the v-hydroxyceramide analog lipid Z and 0–10 mol %
CSO4. Lipid Z esterified onto involucrin was quantitated by isolating
tryptic lipopeptides by C4 HPLC (27). A, reduction of lipopeptide peaks
with increasing CSO4 is shown by superimposing the chromatograms of
lipopeptides selectively retained on the column from the tryptic digest
of 60 mg of involucrin labeled with lipid Z by TGase 1 on SLV with 0 (red
line), 4 (orange line), and 8 (yellow line) mol % CSO4. Quantitation of
these reactions (B) revealed a significant decline of involucrin esterifi-
cation by lipid Z at 3 (*, p , 0.1) or 4 (**, p , 0.01) mol % SLV CSO4
content.
FIG. 6. An assay for the rate of deamidation and putrescine
cross-linking of reactive Gln residues by protein sequencing.
The figure shows superimposed elution chromatograms of residue
Gln133 recovered from peptide peak 22 (see Fig. 2A) of involucrin re-
acted with TGase 1 in the presence of 20 mM putrescine on SLV made
with 0 (black line) or 8 mol % (red line) membrane CSO4. Peak areas
were utilized to calculate the ratio of different Gln modifications by
TGase 1.



















Distribution of products from substate glutamine residues of involucrin after reacting with 0.94 pmol of TGase 1 on SLV formulated with
different CSO4 content
Values were calculated from amino acid analysis after acid hydrolysis data combined with Gln:Glu (:g-glutamylputrescine) ratios from
sequencing yields. Numbers represent mean of three determinations rounded to whole percentage. NA, not available.
Substrates CSO4 Residue Glutamine Glutamate g-Glutamylputrescine e(g-Glutamyl)lysine (g-Glutamyl)lipid Z
mol % %
Only involucrin (wild type) 0 496 49 5 NA 46 NA
133 73 3 NA 24 NA
122 68 32 NA 0 NA
118 82 18 NA 0 NA
107 72 28 NA 0 NA
4 496 47 10 NA 43 NA
133 73 7 NA 20 NA
122 65 35 NA 0 NA
118 79 21 NA 0 NA
107 69 31 NA 0 NA
6 496 46 28 NA 26 NA
133 69 21 NA 10 NA
122 62 38 NA 0 NA
118 75 25 NA 0 NA
107 65 35 NA 0 NA
8 496 45 44 NA 11 NA
133 66 29 NA 5 NA
122 57 43 NA 0 NA
118 73 27 NA 0 NA
107 63 37 NA 0 NA
10 496 37 58 NA 5 NA
133 63 35 NA 2 NA
122 54 46 NA 0 NA
118 70 30 NA 0 NA
107 59 41 NA 0 NA
Involucrin (wild type) 1 20 mM putrescine 0 496 20 1 79 0 NA
133 34 0 66 0 NA
122 31 1 68 0 NA
118 39 0 61 0 NA
107 72 0 38 0 NA
4 496 21 2 77 0 NA
133 33 1 66 0 NA
122 30 3 67 0 NA
118 38 1 61 0 NA
107 37 2 61 0 NA
6 496 19 5 76 0 NA
133 33 3 66 0 NA
122 39 5 66 0 NA
118 37 3 60 0 NA
107 36 3 61 0 NA
8 496 18 9 73 0 NA
133 31 7 62 0 NA
122 28 7 65 0 NA
118 36 6 58 0 NA
107 35 9 56 0 NA
10 496 17 13 70 0 NA
133 30 11 59 0 NA
122 28 10 61 0 NA
118 35 11 54 0 NA
107 34 12 54 0 NA
Involucrin (wild type) 1 1 mol % lipid Z 0 496 51 7 NA 37 5
133 73 3 NA 16 8
122 69 6 NA 0 25
118 83 3 NA 0 14
107 71 5 NA 0 24
4 496 50 15 NA 32 3
133 72 10 NA 13 5
122 67 17 NA 0 16
118 82 8 NA 0 10
107 69 16 NA 0 15
6 496 47 35 NA 17 0
133 69 21 NA 7 3
122 60 36 NA 0 4
118 79 16 NA 0 5
107 68 23 NA 0 9
8 496 46 47 NA 7 0
133 66 31 NA 3 0
122 60 36 NA 0 4
118 76 22 NA 0 2
107 63 33 NA 0 4
10 496 37 61 NA 2 0
133 67 32 NA 1 0



















Substrates CSO4 Residue Glutamine Glutamate g-Glutamylputrescine e(g-Glutamyl)lysine (g-Glutamyl)lipid Z
Only involucrin (K62N mutant) 0 496 19 81 NA 0 NA
133 32 68 NA 0 NA
122 32 68 NA 0 NA
118 38 62 NA 0 NA
107 32 68 NA 0 NA
4 496 18 82 NA 0 NA
133 30 70 NA 0 NA
122 29 71 NA 0 NA
118 37 63 NA 0 NA
107 29 71 NA 0 NA
6 496 16 84 NA 0 NA
133 28 72 NA 0 NA
122 26 74 NA 0 NA
118 37 63 NA 0 NA
107 27 73 NA 0 NA
8 496 13 87 NA 0 NA
133 26 74 NA 0 NA
122 24 76 NA 0 NA
118 35 65 NA 0 NA
107 25 75 NA 0 NA
10 496 11 89 NA 0 NA
133 24 76 NA 0 NA
122 23 77 NA 0 NA
118 33 67 NA 0 NA
107 22 78 NA 0 NA
Involucrin (K62N mutant) 1 20 mM putrescine 0 496 13 0 87 0 NA
133 28 1 71 0 NA
122 29 0 71 0 NA
118 36 1 63 0 NA
107 30 1 69 0 NA
4 496 14 1 85 0 NA
133 27 1 72 0 NA
122 28 2 70 0 NA
118 35 3 62 0 NA
107 30 2 68 0 NA
6 496 12 4 84 0 NA
133 27 4 69 0 NA
122 27 5 68 0 NA
118 34 6 60 0 NA
107 29 7 64 0 NA
8 496 11 11 88 0 NA
133 26 9 65 0 NA
122 26 9 65 0 NA
118 34 8 58 0 NA
107 27 11 62 0 NA
10 496 9 16 75 0 NA
133 25 15 60 0 NA
122 26 14 60 0 NA
118 33 15 52 0 NA
107 26 15 59 0 NA
Involucrin (K62N mutant) 1 1 mol % lipid Z 0 496 25 62 NA 0 13
133 33 60 NA 0 7
122 33 54 NA 0 13
118 39 46 NA 0 15
107 33 51 NA 0 16
4 496 24 74 NA 0 2
133 32 65 NA 0 3
122 31 63 NA 0 6
118 37 54 NA 0 9
107 30 63 NA 0 7
6 496 22 78 NA 0 0
133 31 69 NA 0 0
122 29 70 NA 0 1
118 36 62 NA 0 2
107 29 70 NA 0 1
8 496 21 79 NA 0 0
133 29 71 NA 0 0
122 28 72 NA 0 0
118 34 66 NA 0 0
107 27 63 NA 0 0
10 496 17 83 NA 0 0
133 28 72 NA 0 0
122 26 74 NA 0 0
118 33 67 NA 0 0
107 24 76 NA 0 0
122 58 42 NA 0 0
118 76 22 NA 0 2
107 61 39 NA 0 0


















reactive Gln residues (Fig. 7I; Table III).
When the K62N mutant form of involucrin was reacted with
TGase 1 in the absence of any other glutamyl-acceptor sub-
strate, water was used as the acyl acceptor resulting in near
complete (80–90%) deamidation of the five reactive Gln resi-
dues, the degree of which was not significantly increased with
higher CSO4 levels (Fig. 7, D and J; Table III). In this case,
about 10% of the reactivity of each Gln residue was used for
esterification of lipid Z in the absence of CSO4, but this was lost
to deamidation at $6 mol % CSO4 (Fig. 7, E and K). Again, the
inclusion of 20 mM putrescine into the reactions resulted in
extensive EP formation as expected, although with increasing
amounts of CSO4, the ratio between EP formation and deami-
dation was reduced significantly and was essentially the same
as with the wild type involucrin (compare Fig. 7, F and L with
C and I).
These data indicate the glutamyl donor and acceptor sub-
strate preferences of involucrin cross-linking by membrane
bound TGase 1. Of these, only Gln496, Gln133, and Lys62 can be
used for Ne-(g-glutamyl)lysine cross-link formation, but all the
five reactive glutamines form isopeptide bonds and are esteri-
fied with the ceramide-alcohol lipid Z. We propose that steric
factors might hinder the intimate juxtaposition of Lys62 to the
acyl-enzyme complex when involucrin reacts with TGase 1 on
its Gln107, Gln118, or Gln122.
We also noted that cross-linking through Lys62 decreased the
overall degree of reactivity of the neighboring reactive Gln
residues, in comparison to the uncross-linkable mutant (Fig. 7,
compare panels B and E). This might be a consequence of the
inhibition of substrate diffusion on the SLV surface following
the formation of larger involucrin oligomers, and/or the TGase
1 itself by “stockading” the enzyme by its own products, a
mechanism impossible with the K62A mutant protein. Finally,
cross-linking through Lys62 increased the yield of especially
Gln107, Gln118, Gln122, and Gln133 for esterification (Fig. 7, as
examples, compare panels H and K), This might be a conse-
quence of diminished likelihood for TGase 1-mediated hydrol-
ysis of ester bonds via reversal of once preformed ester linkages
to the acyl-enzyme intermediate, possibly by the same stock-
ading mechanism. We have noted previously that isopeptide
formation is energetically favored over ester formation, since
the latter can be converted to an isopeptide bond by an amine
FIG. 7. The fates of TGase 1 reactive residues Gln496 and Gln122 of involucrin with different substrates at increasing membrane
CSO4 levels. The degrees of modifications of each Gln residue were quantitated as determined in Figs. 5A and 6. Shown here are the data for the
most reactive Gln496 residue (A-F), which participates in both isopeptide and ester bond formation, and for Gln122 (G-L) which is involved only in
ester formation under physiologically relevant conditions. The applied substrates and color codes are noted for each panel.


















(27). Thus it is possible that once an isopeptide bond is, prac-
tically irreversibly (52) formed through Lys62, which is located
near the reactive Gln residues in the head domain of involu-
crin, the bulk of the cross-linked involucrins “saves” ester
bonds from further ester-hydrolase activity by TGase 1
enzyme.
How Does CSO4 Facilitate Deamidation of Reactive Gln Res-
idues?—The most striking observation in the foregoing data is
that the presence of $6% CSO4 in SLV membranes markedly
diverts the TGase 1 reaction mechanism of Gln residues from
isopeptide or ester formation to deamidation. One possible
mechanism for this phenomenon is that excess membrane
CSO4 distorts the structure of the glutamyl acceptor substrate
binding pocket so as to favor the access of water to the acyl-
enzyme thioester intermediate. As water is in great molar
excess over other glutamyl acceptor substrates, and the usage
of water as a substrate is detectable under all assay conditions
using TGases (Fig. 7) (23, 29), it is to be expected that even a
slight conformational change should be sufficient to increase
the opportunity of water to attack the acyl-enzyme thioester
intermediate. The substrate binding pockets of TGases (based
on crystallographic data of factor XIIIa (34, 53)) are imagined
as grooves on the enzyme surface, permitting the binding of two
protruding residues on bulky proteins and the consecutive re-
lease of the cross-linked dimer. The repelling of water from the
active site is done by several juxtaposed hydrophobic side chain
residues surrounding the active site, ideally making the con-
centration of water in the acceptor substrate-binding groove
equal to the concentration of water in the saturated vapor of
the reaction medium. In reality, the use of water may prevent
TGases from being trapped to their glutaminyl substrates in
the absence of other utilizable acceptors, so that this deamida-
tion reaction route may have practical usefulness in regener-
ating the enzyme after interaction with decoy substrates (29).
CSO4 may thus enhance the opportunity for this natural
phenomenon.
Apparently the highest level of membrane CSO4 compatible
with near-optimal cross-link and ceramide ester formation is
#6 mol %, which based on the distribution of total stratum
granulosum lipids, might be 4.5–5.5% by weight (54), although
the actual local surface density of this metabolite might be
lower owing to dilution by plasma membrane lipids or may be
higher owing to the amphipathic character of CSO4. Neverthe-
less, this estimate of 4.5–5.5% is right in the range found in the
lowest layers of normal stratum corneum, and is severalfold
less than that measured in XI epidermis (55).
Conclusions: Consequences for Pathogenesis of Ichthyosis
Diseases—The precise mechanism by which excessive levels of
CSO4 cause defective skin barrier function and disease in XI
has heretofore not been well understood. It was proposed that
since CSO4 has trypsin and chymotrypsin inhibitory properties
in vitro, it might thereby affect breakdown of desmosomes, thus
causing retention hyperkeratoses and abnormal scaling (18).
The strong charge of its sulfate moiety conferring mild deter-
gent properties to CSO4 was shown to interfere with spontane-
ous sheet-formation of epidermal lipids in vivo and thus theo-
rized to affect epidermal barrier function by deranging skin
lipid layers, repressing cholesterol synthesis, and replacing
cholesterol in the lipid sheets (16). More recently, it was dem-
onstrated that CSO4 can induce TGase 1 expression in cultured
keratinocytes (19), but the connection between excess TGase
expression and disease etiology remains unclear. Our present
data offer an alternative biochemical explanation as to how
accumulation of CSO4 may cause XI disease. We show that
CSO4 inhibits the capacity of TGase 1 to perform isopeptide
cross-linking as well as ester linkage of ceramides. Decreased
isopeptide bonding is likely to disrupt the earliest stages of CE
formation, by preventing cross-links between involucrin and
desmoplakin or itself (41, 48) and thus derange the consecutive
series of steps required for protein envelope formation. Fur-
thermore, supraphysiological levels of CSO4 inhibit lipid bound
envelope formation and thus can interfere with the appropriate
orientation and mechanical stability of the intercorneocyte
lipid layers. In these ways, the net result is comparable to loss
of TGase 1 function as observed in lamellar ichthyosis (34, 37,
38). Finally, it is possible that in addition to XI, other skin
diseases having an ichthyosiform phenotype may also arise as
a result of direct or indirect interference with effective TGase 1
function.
Acknowledgments—We are indebted to William W. Idler for expert
assistance in expressing recombinant involucrins and are grateful to
Peter M. Elias for stimulating discussions.
REFERENCES
1. Nemes, Z., and Steinert, P. M. (1999) Exp. Mol. Med. 3, 5–19
2. Ishida-Yamamoto, A., and Iizuka, H. (1998) Exp. Dermatol. 7, 1–10
3. Wertz, P. W., and Downing, D. T. (1991) in Physiology, Biochemistry and
Molecular Biology of the Skin (Goldsmith, L. A., ed) Vol. 1, pp. 205–236,
Oxford University Press, Oxford
4. Marekov, L. N., and Steinert, P. M. (1998) J. Biol. Chem. 273, 17763–17770
5. Wertz, P. W. (1997) Exper. Suppl. (Basel) 78, 227–237
6. Steinberg, D. S. (1978) in The Metabolic Basis of Inherited Disease (Stanbury,
J. B., Wyngaarden, J. B., and Frederickson, D. S., eds) 4th Ed., pp.
688–691, McGraw-Hill, New York
7. De Laurenzi, V., Rogers, G. R., Hamrock, D. J., Marekov, L. N., Steinert, P. M.,
Compton, J. G., Markova, N., and Rizzo, W. B. (1996) Nat. Genet. 12, 52–57
8. Anton-Lamprecht, I. (1992) in Diagnostic Ultrastructure of Non-neoplastic
Diseases (Papadimitrou, J. M., Henderson, D. W., Spagnolo, D. V., eds) pp.
459–551, Churchill Livingstone, New York
9. Shapiro, L. J., Weiss, R., Buxman, M. M., Vidgoff, J., Dimond, R. L., Roller,
J. A., and Wells, R. S. (1978) Lancet 2, 756–757
10. Epstein, E. H., Williams, M. L., and Elias, P. M. (1984) J. Am. Acad. Dermatol.
10, 866–868
11. Ranasinghe, A. W., Wertz, P. W., Downing, D. T., and Mackenzie, I. C. (1986)
J. Invest. Dermatol. 86, 187–190
12. Long, S. A., Wertz, P. W., Strauss, J. S., and Downing, D. T. (1985) Arch
Dermatol. Res. 277, 284–287
13. Williams, M. L. (1992) Semin. Dermatol. 11, 169–175
14. Rehfeld, S. J., Williams, M. L., and Elias, P. M. (1986) Arch Dermatol. Res. 278,
259–263
15. Rehfeld, S. J., Plachy, W. Z., Williams, M. L., and Elias, P. M. (1988) J. Invest.
Dermatol. 91, 499–505
16. Zettersten, E., Man, M. Q., Sato, J., Denda, M., Farrell, A., Ghadially, R.,
Williams, M. L., Feingold, K. R., and Elias, P. M. (1998) J. Invest. Dermatol.
111, 784–790
17. Lykkesfeldt, G., and Hoyer, H. (1983) Lancet 2, 1337–1338
18. Sato, J., Denda, M., Nakanishi, J., Nomura, J., and Koyama, J. (1998) J. In-
vest. Dermatol. 111, 189–193
19. Kawabe, S., Ikuta, T., Ohba, M., Chida, K., Ueda, E., Yamanishi, K., and
Kuroki, T. (1998) J. Invest. Dermatol. 111, 1098–1102
20. Chida, K., Murakami, A., Tagawa, T., Ikuta, T., and Kuroki, T. (1995) Cancer
Res. 55, 4865–4869
21. Ikuta, T., Chida, K., Tajima, O., Matsuura, Y., Iwamori, M., Ueda, Y., Mizuno,
K., Ohno, S., and Kuroki, T. (1994) Cell Growth Differ. 5, 943–947
22. Polakowska, R. R., Eickbush, T., Falciano, V., Razvi, F., and Goldsmith, L. A.
(1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4476–4480
23. Folk, J. E., and Finlayson, J. S. (1977) Adv. Protein Chem. 31, 1–133
24. Greenberg, C. S., Birckbichler, P. J., and Rice, R. H. (1991) FASEB J. 5,
3071–3077
25. Gross, M., and Folk, J. E. (1974) J. Biol. Chem. 249, 3021–3025
26. Parameswaran, K. N., and Lorand, L. (1981) Biochemistry 20, 3703–3711
27. Nemes, Z., Marekov, L. N., Fe´su¨s, L., and Steinert, P. M. (1999) Proc. Natl.
Acad. Sci. U. S. A. 96, 8402–8407
28. Folk, J. E., and Chung, S. I. (1985) Methods Enzymol. 113, 358–375
29. Folk, J. E., and Chung, S. I. (1973) Adv. Enzymol. Relat. Areas Mol. Biol. 38,
109–191
30. Rice, R. H., Mehrpouyan, M., Qin, Q., and Phillips, M. A. (1994) in The
Keratinocyte Handbook (Leigh, I. M., Lane, E. B., and Watt, F. M., eds) pp.
259–274, Cambridge University Press, Cambridge
31. Aeschlimann, D., Koeller, M. K., Allen-Hoffmann, B. L., and Mosher, D. F.
(1998) J. Biol. Chem. 273, 3452–3460
32. Candi, E., Melino, G., Mei, G., Tarcsa, E., Chung, S. I., Marekov, L. N., and
Steinert, P. M. (1995) J. Biol. Chem. 270, 26382–26390
33. Tarcsa, E., Candi, E., Kartasova, T., Idler, W. W., Marekov, L. N., and Steinert,
P. M. (1998) J. Biol. Chem. 273, 23297–23303
34. Candi, E., Melino, G., Lahm, A., Ceci, R., Rossi, A., Kim, I. G., Ciani, B., and
Steinert, P. M. (1998) J. Biol. Chem. 273, 13693–13702
35. Steinert, P. M., Kim, S. Y., Chung, S. I., and Marekov, L. N. (1996) J. Biol.
Chem. 271, 26242–26250
36. Rice, R. H., Rong, X. H., and Chakravarty, R. (1990) Biochem. J. 265, 351–357
37. Russell, L. J., DiGiovanna, J. J., Rogers, G. R., Steinert, P. M., Hashem, N.,
Compton, J. G., and Bale, S. J. (1995) Nat. Genet. 9, 279–283


















38. Huber, M., Rettler, I., Bernasconi, K., Frenk, E., Lavrijsen, S. P., Ponec, M.,
Bon, A., Lautenschlager, S., Schorderet, D. F., and Hohl, D. (1995) Science
267, 525–528
39. Matsuki, M., Yamashita, F., Ishida-Yamamoto, A., Yamada, K., Kinoshita, C.,
Fushiki, S., Ueda, E., Morishima, Y., Tabata, K., Yasuno, H., Hashida, M.,
Iizuka, H., Ikawa, M., Okabe, M., Kondoh, G., Kinoshita, T., Takeda, J., and
Yamanishi, K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1044–1049
40. Eckert, R. L., Yaffe, M. B., Crish, J. F., Murthy, S., Rorke, E. A., and Welter,
J. F. (1993) J. Invest. Dermatol. 100, 613–617
41. Steinert, P. M., and Marekov, L. N. (1997) J. Biol. Chem. 272, 2021–2030
42. Green, H., and Djian, P. (1992) Mol. Biol. Evol. 9, 977–1017
43. Jarnik, M., Simon, M. N., and Steven, A. C. (1998) J. Cell Sci. 111, 1051–1060
44. Nemes, Z., Marekov, L. N., and Steinert, P. M. (1999) J. Biol. Chem. 274,
11013–11021
45. Laemmli, U. K. (1970) Nature 227, 680–685
46. Konigsberg, W. H., and Henderson, L. (1983) Methods Enzymol. 91, 254–259
47. Tarcsa, E., and Fesus, L. (1990) Anal. Biochem. 186, 135–140
48. Steinert, P. M., and Marekov, L. N. (1995) J. Biol. Chem. 270, 17702–17711
49. LaCelle, P. T., Lambert, A., Ekambaram, M. C., Robinson, N. A., and Eckert,
R. L. (1998) Skin Pharmacol. Appl. Skin Physiol. 11, 214–226
50. Eckert, R. L., and Green, H. (1986) Cell 46, 583–589
51. Steinert, P. M., and Marekov, L. N. (1999) Mol. Cell. Biol. 10, 4247–4261
52. Parameswaran, K. N., Cheng, X. F., Chen, E. C., Velasco, P. T., Wilson, J. H.,
and Lorand, L. (1997) J. Biol. Chem. 272, 10311–10317
53. Yee, V. C., Pedersen, L. C., Le Trong, I., Bishop, P. D., Stenkamp, R. E., and
Teller, D. C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7296–7300
54. Williams, M. L. (1991) Adv. Lipid Res. 24, 211–262
55. Elias, P. M., Williams, M. L., Maloney, M. E., Bonifas, J. A., Brown, B. E.,
Grayson, S., and Epstein, E. H., Jr. (1984) J. Clin. Invest. 74, 1414–1421


















Marekov, László Fésüs and Peter M. Steinert
Zoltán Nemes, Máté Demény, Lyuben N.
  
Hydrolysis of Glutamine
Formation of Cross-links and Esters to the 
Transglutaminase 1 Activity from the
Cornified Envelope Assembly by Diverting 




2000, 275:2636-2646.J. Biol. Chem. 
  
 http://www.jbc.org/content/275/4/2636Access the most updated version of this article at 
  
.JBC Affinity SitesFind articles, minireviews, Reflections and Classics on similar topics on the 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/275/4/2636.full.html#ref-list-1
This article cites 52 references, 22 of which can be accessed free at
 at U
N
IV
ERSITY
 O
F D
EBRECEN
 on O
ctober 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
